China Biotech Services (08037.HK) announced the results of a Phase I clinical study of LY007 cell injection in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma (B-NHL) at the 2024 ASCO Annual Meeting in the United States [Google translation]